The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
Saved in:
| Title: | The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. |
|---|---|
| Authors: | Strijbis EM; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Repovic P; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA., Mostert J; Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands., Bowen JD; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA., Uitdehaag BM; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Cutter G; Department of Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, USA., Koch MW; Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, AB, Canada. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Sep; Vol. 28 (10), pp. 1606-1619. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1477-0970 |
|---|---|
| DOI: | 10.1177/13524585221105465 |
